• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by SOPHiA GENETICS SA (Amendment)

    2/20/24 4:55:59 PM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SOPH alert in real time by email
    SC 13G/A 1 d765279dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    SOPHIA GENETICS SA

    (Name of Issuer)

    Ordinary Shares, CHF 0.05 per share

    (Title of Class of Securities)

    H82027105

    (CUSIP Number)

    December 31, 2023

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. H82027105       13G

     

     1.    

    NAMES OF REPORTING PERSONS

     

    Balderton Capital VI, S.L.P.

     2.   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a) ☐  (b) ☒

     

     3.   

    SEC USE ONLY

     

     4.   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5.    

    SOLE VOTING POWER

     

    0

        6.   

    SHARED VOTING POWER

     

    3,361,880 (1)

        7.   

    SOLE DISPOSITIVE POWER

     

    0

        8.   

    SHARED DISPOSITIVE POWER

     

    3,361,880 (1)

     9.    

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,361,880 (1)

    10.   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    ☐

    11.   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.1% (2)

    12.   

    TYPE OF REPORTING PERSON (see instructions)

     

    PN

     

    (1)

    All such shares are held of record by BCVI (as defined in Item 2(a) of the Original Schedule 13G (as defined in the Explanatory Note below)). BCVI Sarl (as defined in Item 2(a) of the Original Schedule 13G) is the managing general partner of BCVI and may be deemed to have voting, investment and dispositive power with respect to these securities. The Managers (as defined in Item 4 of the Original Schedule 13G) are the managers of BCVI Sarl and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    This calculation is based upon 65,302,753 of the Issuer’s Ordinary Shares outstanding as of December 31, 2023, as reported by the Issuer to the Reporting Persons.


    CUSIP No. H82027105       13G

     

     1.    

    NAMES OF REPORTING PERSONS

     

    Balderton Capital General Partner VI, S.á.r.l.

     2.   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a) ☐  (b) ☒

     

     3.   

    SEC USE ONLY

     

     4.   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5.    

    SOLE VOTING POWER

     

    0

        6.   

    SHARED VOTING POWER

     

    3,361,880 (1)

        7.   

    SOLE DISPOSITIVE POWER

     

    0

        8.   

    SHARED DISPOSITIVE POWER

     

    3,361,880 (1)

     9.    

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,361,880 (1)

    10.   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    ☐

    11.   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.1% (2)

    12.   

    TYPE OF REPORTING PERSON (see instructions)

     

    FI

     

    (1)

    All such shares are held of record by BCVI. BCVI Sarl is the managing general partner of BCVI and may be deemed to have voting, investment and dispositive power with respect to these securities. The Managers are the managers of BCVI Sarl and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    This calculation is based upon 65,302,753 of the Issuer’s Ordinary Shares outstanding as of December 31, 2023, as reported by the Issuer to the Reporting Persons.


    CUSIP No. H82027105       13G

     

    Explanatory Note: This Amendment No. 2 (this “Amendment No. 2”) is being filed to amend and restate the Schedule 13G Amendment No. 1 filed by the Reporting Persons on February 13, 2024 (“Amendment No. 1”) to amend and supplement the original Schedule 13G filed with the United States Securities and Exchange Commission (the “Commission”) on February 10, 2022 (together with Amendment No. 1, the “Original Schedule 13G”). This Amendment No. 2 updates the percentage ownership of the Issuer’s Ordinary Shares by each of the Reporting Persons based on additional information shared by the Issuer with the Reporting Persons regarding the number of Ordinary Shares outstanding after the Reporting Persons filed Amendment No. 1. This amended Schedule 13 amends and restates in its entirety the information reported in Amendment No. 1. Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13G remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment No. 2 have the meanings ascribed to them in the Original Schedule 13G.

     

    Item 4.

    Ownership.

     

      (a)

    Amount beneficially owned:

    See Row 9 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (b)

    Percent of class:

    See Row 11 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote

    See Row 5 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (ii)

    Shared power to vote or to direct the vote

    See Row 6 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (iii)

    Sole power to dispose or to direct the disposition of

    See Row 7 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (iv)

    Shared power to dispose or to direct the disposition of

    See Row 8 of the cover page for each Reporting Person and the corresponding footnotes.*

     

    *

    Except to the extent of his, her or its pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such Ordinary Shares, except for the shares, if any, such Reporting Person holds of record.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

     

    ☐


    CUSIP No. H82027105       13G

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 20, 2024

     

    BALDERTON CAPITAL VI, S.L.P.
    By: Balderton Capital General Partner VI, S.á.r.l.
    Its: Managing General Partner
    By:   /s/ Petr Klimo
    Name:   Petr Klimo
    Its:   Manager
    BALDERTON CAPITAL GENERAL PARTNER VI, S.Á.R.L.
    By:   /s/ Petr Klimo
    Name:   Petr Klimo
    Its:   Manager
    Get the next $SOPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SOPH

    DatePrice TargetRatingAnalyst
    12/18/2024$11.00Buy
    Craig Hallum
    8/7/2024$10.00 → $5.00Overweight → Equal-Weight
    Morgan Stanley
    6/27/2024$6.00Buy
    Guggenheim
    11/29/2023$8.00Outperform
    RBC Capital Mkts
    7/5/2023$10.00Overweight
    JP Morgan
    1/3/2023$6.00Buy
    BTIG Research
    11/23/2022$2.00Neutral
    Credit Suisse
    2/15/2022$23.00 → $18.00Overweight
    Morgan Stanley
    More analyst ratings

    $SOPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SOPHiA GENETICS Reports First Quarter 2025 Results

      BOSTON and ROLLE, Switzerland, May 6, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Revenue was $17.8 million, up 13% year-over-year or 15% on a constant currency basisGross margin was 68.7% on a reported basis and 75.7% on an adjusted basis, up from 65.9% and 70.5% in the prior year period, respectivelyIFRS net loss increased 27% year-over-year to $17.4 million (including a net foreign excha

      5/6/25 6:45:00 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR

      BOSTON and ROLLE, Switzerland, April 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced the expansion of its ongoing collaboration with AstraZeneca (NASDAQ:AZN) to accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™ globally. Building on the initial collaboration announced in October 2024, this new phase will extend the test's reach to a total of 30 clinical institutions worldwide in 2025. Developed in collaboration with Memorial Sloan Kettering Cancer Cen

      4/28/25 12:00:00 PM ET
      $AZN
      $SOPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • SOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025

      BOSTON and ROLLE, Switzerland, April 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter 2025 before U.S. markets open on Tuesday, May 6, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will be

      4/22/25 8:00:00 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SOPH
    Leadership Updates

    Live Leadership Updates

    See more
    • SOPHiA GENETICS Promotes Ross Muken to President and Appoints George Cardoza as Chief Financial Officer

      BOSTON and ROLLE, Switzerland, Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Ross Muken, previously Chief Financial Officer ("CFO") and Chief Operating Officer ("COO"), has been promoted to company President, effective November 5, 2024. George Cardoza has been appointed as the company's new CFO. In the newly created role of company President, Ross Muken will oversee SOPHiA GENETICS's global business operations and work even more closely on strategic planning with CEO, Jurgi C

      11/5/24 6:32:00 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SOPHiA GENETICS Launches Global Consortium, SOPHiA UNITY, to Accelerate Cancer Research, Drug Development, and Data-Driven Patient Care

      New collective intelligence network to enable the most advanced research in oncology in support of precision medicine BOSTON and ROLLE, Switzerland, May 30, 2024 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced SOPHiA UNITY, a new data-driven consortium designed to accelerate cancer research globally. SOPHiA UNITY aims to bring together leading healthcare institutions to progress a shared goal of furthering cancer research, advancing drug development and supporting data-driven patient care.

      5/30/24 12:19:00 PM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SOPHiA GENETICS Announces Nomination of Lila Tretikov to Board of Directors

      Microsoft's Deputy Chief Technology Officer to be appointed at Annual Shareholders' Meeting BOSTON and LAUSANNE, Switzerland, May 31, 2023 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced the nomination of Lila Tretikov to its Board of Directors. The Board of Directors has proposed the appointment of Tretikov as a member of the board at the Annual General Meeting of Shareholders of SOPHiA GENETICS SA on June 26, 2023. An award-winning powerhouse in the global technology

      5/31/23 9:12:00 AM ET
      $SOPH
      $XYL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Fluid Controls
      Industrials

    $SOPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by SOPHiA GENETICS SA

      SC 13G/A - SOPHiA GENETICS SA (0001840706) (Subject)

      11/13/24 3:31:21 PM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by SOPHiA GENETICS SA (Amendment)

      SC 13G/A - SOPHiA GENETICS SA (0001840706) (Subject)

      2/20/24 4:55:59 PM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by SOPHiA GENETICS SA (Amendment)

      SC 13G/A - SOPHiA GENETICS SA (0001840706) (Subject)

      2/14/24 11:23:25 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SOPH
    SEC Filings

    See more
    • SEC Form 144 filed by SOPHiA GENETICS SA

      144 - SOPHiA GENETICS SA (0001840706) (Subject)

      5/19/25 4:21:14 PM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by SOPHiA GENETICS SA

      6-K - SOPHiA GENETICS SA (0001840706) (Filer)

      5/16/25 9:53:25 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by SOPHiA GENETICS SA

      6-K - SOPHiA GENETICS SA (0001840706) (Filer)

      5/8/25 2:23:03 PM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SOPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on SOPHiA GENETICS SA with a new price target

      Craig Hallum initiated coverage of SOPHiA GENETICS SA with a rating of Buy and set a new price target of $11.00

      12/18/24 7:54:16 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SOPHiA GENETICS SA downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded SOPHiA GENETICS SA from Overweight to Equal-Weight and set a new price target of $5.00 from $10.00 previously

      8/7/24 11:39:17 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Guggenheim initiated coverage on SOPHiA GENETICS SA with a new price target

      Guggenheim initiated coverage of SOPHiA GENETICS SA with a rating of Buy and set a new price target of $6.00

      6/27/24 7:51:58 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SOPH
    Financials

    Live finance-specific insights

    See more
    • SOPHiA GENETICS Reports First Quarter 2025 Results

      BOSTON and ROLLE, Switzerland, May 6, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Revenue was $17.8 million, up 13% year-over-year or 15% on a constant currency basisGross margin was 68.7% on a reported basis and 75.7% on an adjusted basis, up from 65.9% and 70.5% in the prior year period, respectivelyIFRS net loss increased 27% year-over-year to $17.4 million (including a net foreign excha

      5/6/25 6:45:00 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025

      BOSTON and ROLLE, Switzerland, April 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter 2025 before U.S. markets open on Tuesday, May 6, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will be

      4/22/25 8:00:00 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SOPHiA GENETICS Reports Fourth Quarter and Full Year 2024 Results

      BOSTON and ROLLE, Switzerland, March 4, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for its fourth quarter and fiscal year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights Revenue was $17.7 million, up 4% year-over-year or 6% on a constant currency basis excluding COVID-19-related revenue Gross margin was 68.2% on a reported basis and 74.2% on an adjusted basis, compared to 69.8% and 73.4% in the prior year period, respectivelyOperating loss was $17.4 m

      3/4/25 6:45:00 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care